While recent data from the Centers for Disease Control and Prevention (CDC) found a first annual decrease in opioid-related deaths since 2018 in the U.S., fentanyl poisonings are still on the rise and over 100,000 lives were still lost to preventable opioid overdose death in 2023.2 Williams added, "In addition to working with critical public interest groups and broadening consumer access in the OTC retail setting, Emergent is also engaging with partners who are aligned with our mission to expand access, awa ...

Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard of care for opioid overdose reversal in a community setting New topline survey findings reinforce the need for continued education on naloxone While recent data from the Centers for Disease Control and Prevention (CDC) found a first annual decrease in opioid-related deaths since 2018 in the U.S., fentanyl poisonings are still on the rise and over 100,000 lives were still lost to preventable opioid overdose deat ...

GAITHERSBURG, Md., May 10, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that its 2024 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 23, 2024 at 9:00 am eastern time. HOW TO PARTICIPATE IN THE VIRTUAL ANNUAL MEETINGAs described in the annual proxy statement, stockholders of record are eligible to participate in and ask questions during the Virtual Annual Meeting. Visit this webpage and enter the 16-digit Control ...

Emergent BioSolutions (NYSE:EBS) layoffs are in the news as the life sciences company prepares to cut jobs and close down certain facilities.According to a release from Emergent BioSolutions, these layoffs will affect 300 of its employees. The company also says that it will be closing 85 open positions that are currently vacant.The job cuts will also see Emergent BioSolutions close down two of its locations. That includes its Baltimore-Bayview Drug Substance manufacturing facility and Rockville, Maryland Dr ...

Emergent BioSolutions Inc. (NYSE:EBS) Q1 2024 Earnings Call Transcript May 1, 2024 5:00 PM ET Company Participants Joe Papa - President and CEO Rich Lindahl - EVP and CFO Paul Williams - SVP, Products Business Operator Good afternoon, everyone. I'm the operator for today's call. Thank you for joining today as Emergent discusses their operational and financial results for the first quarter of 2024. As is customary, today's call is open to all participants, and the call is being recorded and is copyrighted by ...

| --- | --- | |-----------|-------| | | | | | | | | | | | | | Q1 2024 | | | Financial | | | Results | | | Update | | | | | | | | | | | | | | | | | | May 1, 2024 | | | | | | | | | | | | | | | | | | | | 1 PROPRIETARY AND CONFIDENTIAL 2 Q1 2024 Update Introduction INTRODUCTION Safe Harbor Statement/Trademarks | --- | --- | --- | |-------|-------|-------| | Presenter \nJoseph C. Papa | • | Topic(s) \nTransformation Plan Update | | President and CEO | | | | Rich Lindahl | • | Q1 2024 Financial Review | | EVP, CF ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33137 EMERGENT BIOSOLUTIONS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 14-1902018 (State or Other Jurisdiction o ...

EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS FINANCIAL HIGHLIGHTS (1) "We delivered a strong quarter with growth across all our key products," said Joe Papa, President and CEO at Emergent. "We also took significant actions to improve our debt position, reduce operating expenses and strengthen our financial flexibility. Emergent's transformation will not happen overnight. The actions we are implementing today, combined with the assets Emergent possesses, will enable us to move faster, r ...

Proactive changes aim to ensure long-term sustainability and growth, optimize operations, streamline processes, and allocate resources more efficientlyReorganization will align with evolving business goals, strategic priorities and new operational planOverall efforts expected to deliver annual cost savings of approximately $80 million  GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced the next phase of its new operational plan that consolidates operations, ...

Nearly 9 in 10 Americans surveyed agree opioid overdoses are a concern for teenagers and college students; parents in the survey want life-saving treatment to be easily accessible in case of an emergency GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the results of a new national public opinion survey showing that more than 90 percent of Americans surveyed recognize opioid overdoses are a pressing concern for teenagers and college students, and more ...